Home / Market News / $ODTX
benzinga Corporate Catalyst Impact 65/100 ● neutral

Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42

Oct 9, 2026, 11:01 AM UTC · Primary ticker $ODTX

Raymond James has initiated coverage on Odyssey Therapeutics (ODTX) with an Outperform rating and a $42 price target. This analyst coverage signals increased institutional interest and provides a new valuation benchmark for the company.

Raymond James analyst Thomas Deal initiated coverage on Odyssey Therapeutics (ODTX) with an Outperform rating and a $42 price target. This event is significant as new analyst coverage, especially with a positive rating and a specific price target, often brings increased visibility and investor confidence to a stock. For ODTX, this could lead to short-term upward price momentum as investors react to the positive sentiment and new valuation. In the long term, sustained positive analyst coverage can contribute to a more stable investor base and potentially higher trading volumes. The key opportunity for traders is to capitalize on the potential immediate price appreciation following the news.

$ODTX positive New analyst coverage and positive rating
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.